Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? - Wikidata - awgldk - TriplyDB

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

http://www.wikidata.org/entity/Q34743469

about

Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation How I treat pediatric acute myeloid leukemia Childhood acute myeloid leukaemia Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Current Management of Childhood Acute Myeloid Leukemia.Costs of second allogeneic hematopoietic cell transplantation.Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics.Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Prevalence of hematopoietic cell transplant survivors in the United States.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Caregiver Sleep and Patient Neutrophil Engraftment in Allogeneic Hematopoietic Stem Cell Transplant: A Secondary Analysis.Aging: Treating the Older Patient.Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation.Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation.Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision Central nervous system complications after allogeneic hematopoietic stem cell transplantation.Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

P2860

Q26861648-20DA4A80-486B-4430-A836-E86428BEEA20 Q26992280-A0623BFA-EE4B-43C7-9BA6-AB477429CCF3 Q27005960-A7608BB4-9F59-4120-95C4-6279C6D27174 Q30240140-E80C4591-2495-495E-835D-305A0DDF7D94 Q30244036-2BABC7AD-5BA2-4231-9404-68A674634297 Q30540989-00867F04-37D9-41D3-8582-1CC62158611D Q30577948-4436E340-E46F-49FA-A01A-A91BC47C5762 Q33573495-81624432-4CA9-48ED-ABC9-EECA8F9DEC02 Q33870341-FE77EDC5-9817-4574-9120-96D80531CDCD Q34749365-412197A0-2337-4D3B-963C-FF40076E01AF Q35285004-B1006355-EE6C-4000-A6FC-F7DFF9724893 Q35782852-0A255B74-1274-4132-9E71-8BEE65046AF6 Q35849342-95AABA46-2345-4145-AEA7-0AD30EA6E1FE Q36087195-DDC627BA-0A2B-469C-AD86-61933B236391 Q36264692-471CB604-9004-4E26-876A-1AFC255B2437 Q36543686-4630A65C-CC6D-432D-BDEE-0B0C913FA490 Q36715943-4463AD5B-F5AD-46BC-ACAA-4FAD7CAF5A8B Q37188807-DF650C07-9DA0-4FA3-ACC3-387A19C4D097 Q37370651-047696AC-07EE-4931-871F-F6DB6607D90A Q37443163-EAB06637-6459-46C6-AA9B-6E209C86BFAC Q37575215-E707773E-EFB0-4104-9949-6B274A519CA8 Q38018908-ED57292E-5EAD-4C76-84DD-B44E779A4466 Q38143516-0B23B9BA-40F4-443B-9D6A-065BD7389237 Q38207595-3206BEDF-9554-413D-8418-8EE23CBA0367 Q38777460-3C6E28A5-C166-4716-B2B9-B9FED4EEBDC9 Q38786591-23CE2E57-D566-430F-96D1-74F8E676E6FA Q39013605-0B415319-7676-44B2-98F4-741A6EE67B9C Q39049349-4489D0CA-41AB-4593-8A15-B40080811486 Q39716725-994F7B72-05E7-44EF-A732-E250D84D8325 Q40122841-FAE45C61-A2C2-4EAF-AA99-63F8E38DB65E Q40216708-3E6D8BF1-4903-46A2-8BE8-E277C18E0E3C Q40288619-FF2CCC5C-710E-4834-B0E1-0B30D1AB1E4E Q40727176-6EC9CB86-C198-4A4C-B232-9DABC96400C2 Q40799791-62AAAD92-071B-4884-B49C-5558A2FBDBB7 Q41031192-91836CC5-4BF3-4D25-A0D0-A3DD48CE4BB3 Q41663868-FF925356-15B1-4975-BFAD-8B2E3467336C Q41688144-7186A33C-A082-4385-A2D8-3949E3A48D34 Q41879404-F51911F0-DDC0-4768-8D1E-7D899F796DE6 Q41923053-C345CD4D-4298-4D0B-9643-879BD35D5E94 Q44059940-AACEA850-6898-4190-897B-1274151ED75F

P2860

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

http://www.wikidata.org/entity/Q34743469

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reducing the risk for transpla ...... w much progress has been made?

@ast

Reducing the risk for transpla ...... w much progress has been made?

@en

Reducing the risk for transpla ...... w much progress has been made?

@nl

type

label

Reducing the risk for transpla ...... w much progress has been made?

@ast

Reducing the risk for transpla ...... w much progress has been made?

@en

Reducing the risk for transpla ...... w much progress has been made?

@nl

prefLabel

Reducing the risk for transpla ...... w much progress has been made?

@ast

Reducing the risk for transpla ...... w much progress has been made?

@en

Reducing the risk for transpla ...... w much progress has been made?

@nl

P1433

Q34743469-88CEAF84-34B2-4AD3-B43D-AD814718DA7F

P1476

Q34743469-92130A8C-48B8-423D-99F1-339BCF9DE4CC

P2093

Q34743469-0169E15E-3EF0-4563-A466-BA77E12A3452

Q34743469-0669883E-5DE0-42ED-A734-9E9164AD8F1B

Q34743469-0C8A99C1-4668-42E3-AC52-EBE7DD384AB0

Q34743469-125DFC45-8916-4073-A921-95363DF61A0C

Q34743469-14F4FC0F-1F72-4AA3-A3DF-6553245B755F

Q34743469-195639C9-C8EC-4B82-9C2F-C94EA97C1727

Q34743469-23B81E69-4A26-49BC-B0BE-5F389D082686

Q34743469-2F8C5ED0-ACD0-4ADE-8A39-64C4659126EB

Q34743469-48472149-1336-4E0A-9398-3CC19C3B6743

Q34743469-51E29944-4B5D-4CC8-B623-2B77A0D18C3C

P2860

Q34743469-056B37E2-FF3E-4C67-AAA6-B8F071C6011A

Q34743469-0C7987DC-0403-4986-8084-E5AA77C35BDC

Q34743469-0EA0F3ED-5B1F-459C-B743-29F9EBB62811

Q34743469-109F5411-A09C-442D-98F7-7250E2508581

Q34743469-1BD4BCCC-A177-4470-90F3-56A5C5535A18

Q34743469-226DBDE7-1526-44E9-94FA-2BD01D2B7A6F

Q34743469-49BEB63F-BA54-43EB-B616-F9B3166A12F1

Q34743469-64C10A56-8DD9-4851-8672-F87D6CF265E6

Q34743469-729C6C16-B8DA-47A9-8529-3DE839CC0539

Q34743469-790E876A-3608-43BC-A536-121004B8621A

P304

Q34743469-FD7B8E36-4C7A-46B5-A76A-45308608A6F4

P31

Q34743469-DB3A2A90-BF76-4D44-8703-4FE3C9E86813

P356

Q34743469-BF50BB2A-A5DD-42A1-B321-8ED8076A010C

P407

Q34743469-D20D1DC0-4FEE-43A3-B0F9-63DAF232321A

P433

Q34743469-EDB4EF4C-F884-4B1D-8328-02C1DF16CE69

P478

Q34743469-F9218193-5E7C-405D-82AA-6A1E2626CF60

P50

Q34743469-91AF7E2C-18D7-4894-80C6-6D2BD9ECCD39

P577

Q34743469-F79CDF35-5AB9-423D-9369-896C75FE18D5

P698

Q34743469-A38B65A4-7E00-4808-8EB7-E8DE1C1F528B

P932

Q34743469-3C8F15AB-9E2B-4FD3-8C9C-063CE3C99D76

P356

JCO.2010.32.5001

P1433

Journal of Clinical Oncology

P1476

Reducing the risk for transpla ...... w much progress has been made?

@en

P2093

Andrea A Bacigalupo

http://www.w3.org/2001/XMLSchema#string

Brent R Logan

http://www.w3.org/2001/XMLSchema#string

Christopher N Bredeson

http://www.w3.org/2001/XMLSchema#string

Franklin O Smith

http://www.w3.org/2001/XMLSchema#string

Gregory A Hale

http://www.w3.org/2001/XMLSchema#string

Hanna Jean Khoury

http://www.w3.org/2001/XMLSchema#string

J Douglas Rizzo

http://www.w3.org/2001/XMLSchema#string

John T Horan

http://www.w3.org/2001/XMLSchema#string

Karen K Ballen

http://www.w3.org/2001/XMLSchema#string

Manza-A Agovi-Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality.

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy

Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.

P304

805-813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.5001

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Hillard M Lazarus

P577

2011-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21220593

http://www.w3.org/2001/XMLSchema#string

P932

3068057

http://www.w3.org/2001/XMLSchema#string